HSITF:OTO-Hadasit Bio Holdings Ltd (USD)

COMMON STOCK | Biotechnology | OTC Pink

Last Closing

USD 0.13

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Hadasit Bio Holdings Ltd operates as an investment holding company. The Company through it holdings is engaged in research and development in the medical and biotechnology fields.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

-3.39 (-2.46%)

USD 599.53B
CSLLY CSL Ltd

+1.51 (+1.63%)

USD 90.20B
CMXHF CSL Limited

+4.30 (+2.33%)

USD 90.20B
UCBJF UCB SA

N/A

USD 26.60B
UCBJY UCB SA ADR

+1.26 (+1.84%)

USD 26.44B
ARGNF argenx SE

N/A

USD 22.20B
GNMSF Genmab A/S

-8.61 (-3.03%)

USD 18.02B
WXIBF WuXi Biologics

N/A

USD 7.05B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.91B
SBMFF Sino Biopharmaceutical Limited

+0.05 (+16.19%)

USD 6.91B

ETFs Containing HSITF

XS3R:LSE Xtrackers MSCI Europe Con.. 5.06 % 0.00 %

+82.00 (+0.95%)

USD 0.07B
DXSK:F Xtrackers - Stoxx Europe .. 5.06 % 0.00 %

+0.24 (+0.95%)

USD 0.07B
DXSK:XETRA Xtrackers - Stoxx Europe .. 5.06 % 0.00 %

+0.94 (+0.95%)

USD 0.07B
EMOM:PA BNP Paribas Easy ESG Equi.. 4.95 % 0.00 %

-0.18 (0.95%)

USD 2.00M
MOED:PA BNP Paribas Easy - Equity.. 4.95 % 0.00 %

-0.10 (0.95%)

USD 0.30M
MOED:F BNP Paribas Easy - Equity.. 4.95 % 0.00 %

+0.80 (+0.95%)

USD 2.20M
MOEU:F BNP Paribas Easy - Equity.. 4.95 % 0.00 %

+1.08 (+0.95%)

USD 2.55M
MOED:XETRA BNP Paribas Easy - Equity.. 4.95 % 0.00 %

N/A

USD 2.20M
MOEU:XETRA BNP Paribas Easy ESG Equi.. 4.95 % 0.00 %

-0.24 (0.95%)

USD 2.20M
EWN iShares MSCI Netherlands .. 3.57 % 0.47 %

-0.01 (0.95%)

USD 0.27B
IAEX:LSE iShares AEX UCITS ETF EUR.. 3.00 % 0.00 %

-5.50 (0.95%)

USD 0.65B
3SUE:XETRA iShares MSCI World Consum.. 2.89 % 0.00 %

+0.02 (+0.95%)

USD 0.09B
ESIS:LSE iShares MSCI Europe Consu.. 2.51 % 0.00 %

+0.04 (+0.95%)

USD 0.81B
CSTP:LSE SPDR® MSCI Europe Consum.. 2.48 % 0.00 %

+1.68 (+0.95%)

USD 0.14B
STS:PA SSgA SPDR ETFs Europe II .. 2.48 % 0.00 %

+1.75 (+0.95%)

USD 0.16B
SPYC:F SSgA SPDR ETFs Europe II .. 2.48 % 0.00 %

+1.25 (+0.95%)

USD 0.16B
SPYC:XETRA SPDR® MSCI Europe Consum.. 2.48 % 0.00 %

+1.70 (+0.95%)

USD 0.16B
XFI:CA 1.96 % 0.51 %

N/A

N/A
UD02:LSE UBS(Lux)Fund Solutions .. 1.84 % 0.00 %

+8.20 (+0.95%)

USD 0.05B
UIMY:F UBS (Lux) Fund Solutions .. 1.82 % 0.00 %

+0.06 (+0.95%)

USD 0.05B
UIMY:XETRA UBS(Lux)Fund Solutions .. 1.82 % 0.00 %

+0.07 (+0.95%)

USD 0.05B
SRIE:PA BNP Paribas Easy MSCI Eur.. 1.53 % 0.00 %

+0.12 (+0.95%)

USD 0.22B
ZSRI:F BNP Paribas Easy - MSCI E.. 1.53 % 0.00 %

N/A

USD 1.45B
ZSRI:XETRA BNP Paribas Easy MSCI Eur.. 1.53 % 0.00 %

+0.09 (+0.95%)

USD 1.45B
MVAE:LSE 0.77 % 0.00 %

N/A

N/A
MVEX:LSE 0.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.00% 20% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.00% 20% F 10% F
Trailing 12 Months  
Capital Gain -62.86% 32% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -62.86% 32% F 17% F
Trailing 5 Years  
Capital Gain -89.76% 42% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.76% 42% F 20% F
Average Annual (5 Year Horizon)  
Capital Gain -12.99% 36% F 19% F
Dividend Return -12.99% 36% F 18% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 75.22% 52% F 39% F
Risk Adjusted Return -17.27% 38% F 26% F
Market Capitalization 0.07B 31% F 23% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector